About Modifi Bio
Modifi Bio is a company based in New Haven (United States) founded in 2021 by Ranjit Bindra and Kingson Lin was acquired by Merck in October 2024. Modifi Bio has raised $11.7 million across 3 funding rounds from investors including Merck, BrightEdge and Yale University. Modifi Bio operates in a competitive market with competitors including Biodexa Pharmaceuticals, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
- Headquarter New Haven, United States
- Founders Ranjit Bindra, Kingson Lin
- SectorsHealthcare
- Email••••••••
- Website modifibio.com
- Social LinkedIn
- Acquired by Merck (Oct 2024)
- Legal Name Modifi Biosciences, Inc.
Funding Insights of Modifi Bio
Modifi Bio has successfully raised a total of $11.7M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $995.5 thousand completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.7M
- Total Rounds 3
- Last Round Seed — $995,503
- First Round $6.4M
(Jul 2022)
- Investors Count 8
All 3 funding rounds of Modifi Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $995,503 | Seed | – | – | – |
| Oct 2023 | $4.3M | Seed | – | Pathway Bioventures, The Sontag Foundation | |
| Jul 2022 | $6.4M | Seed | – | – |
9 investors in total: 9 institutional.
Investors in Modifi Bio
Modifi Bio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, BrightEdge and Yale University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science companies are targeted for private equity investments. | 2013 | highcape.com | New York, United States | |
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
Private equity and debt investments are focused on multiple sectors. | – | ironwoodcap.com | Avon, United States | |
Philanthropic capital is invested to advance brain tumor treatments. | – | braintumorinvestmentfund.org | Newton, United States | |
Pathway Bioventures is focused on seed-stage investments in precision therapeutics. | – | pathwaybioventures.com | Chicago, United States | |
Private foundation of Northeast Florida focused on the healthcare sector | 2002 | sontagfoundation.org | - | |
Search engine optimization tools for enterprises are provided. | 2007 | brightedge.com | San Mateo, United States | |
Multiple courses and degrees are offered across diversified academic streams. | 1701 | yale.edu | United States | |
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom |
Investor details for Modifi Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Modifi Bio
4 people are tracked at Modifi Bio (4 in leadership).
| Name | Role | Group |
|---|---|---|
Ranjit Bindra | Co-Founder | Leadership |
Kingson Lin | Co-Founder | Leadership |
Patricia Lorusso | Associate Director For Experimental Therapeutics | Leadership |
Bruce Ruggeri | Vice President, Pharmacology | Leadership |
Complete people profiles for Modifi Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Modifi Bio
4 dated milestones of Modifi Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Modifi Bio is founded.
- Funding First funding round of $6.4M.
- Funding Latest funding round, Seed, of $996K.
- Exit Acquired by Merck.
Competitors of Modifi Bio
Modifi Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biodexa Pharmaceuticals, OncoSynergy, Plex Pharmaceuticals, Flag Therapeutics and Purposeful, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biodexapharma.com | 2000 | Cardiff, United Kingdom | $6.79M | – | Therapeutics for aggressive rare brain cancers are developed. | |
| oncosynergy.com | 2011 | San Francisco, United States | $26.71M | 3 | Resistance mechanism inhibitors for cancer treatment are developed. | |
| plexpharma.com | 2009 | San Diego, United States | – | – | Discovering small molecules for diseases caused by protein misfolding such as Parkinson's. | |
| flagtherapeutics.com | 2013 | Raleigh, United States | $1.37M | – | Small molecule therapeutics for difficult-to-treat cancers are developed. | |
| purposeful.eu | 2000 | Athens, Greece | $293,896 | – | Purposeful is engaged in discovering treatments for rare diseases. | |
| cnspharma.com | 2017 | Houston, United States | – | 5 | Treatments for brain and central nervous system cancers are developed. | |
| diakonosoncology.com | 2022 | Houston, United States | $31.4M | – | Immunotherapeutics for various cancers are developed and provided by Diakonos. | |
| curtanapharma.com | 2013 | Austin, United States | – | – | Small molecule therapeutics targeting transcription factors for glioblastoma are developed. | |
| systimmune.com | 2014 | Redmond, United States | – | 36 | Develops therapeutic antibodies and ADCs to target cancer cells. |
Detailed competitors of Modifi Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Modifi Bio
Complete news archive for Modifi Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Modifi Bio
10 companies that operate in the same segment as Modifi Bio (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Modifi Bio
Modifi Bio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Modifi Bio is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Modifi Bio is a funded company, having raised a total of $11.7M across 3 funding rounds to date. The company's 1st funding round was a Seed of $6.4M, raised on Jul 2022.
Developer of therapeutics for the treatment of cancer. The company focuses on developing therapeutics that uniquely target specific acquired cancer cell DNA mutations for the treatment of all cancer types.
Modifi Bio's top competitors include Diakonos, Biodexa Pharmaceuticals and OncoSynergy.
Modifi Bio has 9 investors. Key investors include Merck, BrightEdge, Yale University, HighCape Capital, and The Sontag Foundation.
Modifi Bio operates through Modifi Biosciences, Inc..
Yes. Modifi Bio was acquired by Merck in October 2024.